Show simple item record

dc.contributor.authorElli, Stefano
dc.contributor.authorBojkova, Denisa
dc.contributor.authorBechtel, Marco
dc.contributor.authorVial, Thomas
dc.contributor.authorBoltz, David
dc.contributor.authorMuzzio, Miguel
dc.contributor.authorPeng, Xinjian
dc.contributor.authorSala, Federico
dc.contributor.authorCosentino, Cesare
dc.contributor.authorGoy, Andrew
dc.contributor.authorGuerrini, Marco
dc.contributor.authorMüller, Lutz
dc.contributor.authorCinatl, Jindrich
dc.contributor.authorMargitich, Victor
dc.contributor.authorTe Velthuis, Aartjan JW
dc.date.accessioned2021-10-30T01:13:03Z
dc.date.available2021-10-30T01:13:03Z
dc.date.issued2021-09-17
dc.identifier.issn2227-9059
dc.identifier.otherPMC8467925
dc.identifier.other34572438
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330091
dc.description.abstractPandemic SARS-CoV-2 causes a mild to severe respiratory disease called coronavirus disease 2019 (COVID-19). While control of the SARS-CoV-2 spread partly depends on vaccine-induced or naturally acquired protective herd immunity, antiviral strategies are still needed to manage COVID-19. Enisamium is an inhibitor of influenza A and B viruses in cell culture and clinically approved in countries of the Commonwealth of Independent States. In vitro, enisamium acts through metabolite VR17-04 and inhibits the activity of the influenza A virus RNA polymerase. Here we show that enisamium can inhibit coronavirus infections in NHBE and Caco-2 cells, and the activity of the SARS-CoV-2 RNA polymerase in vitro. Docking and molecular dynamics simulations provide insight into the mechanism of action and indicate that enisamium metabolite VR17-04 prevents GTP and UTP incorporation. Overall, these results suggest that enisamium is an inhibitor of SARS-CoV-2 RNA synthesis in vitro.
dc.languageeng
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceessn: 2227-9059
dc.sourcenlmid: 101691304
dc.subjectMolecular dynamics simulation
dc.subjectRNA polymerase
dc.subjectCovid-19
dc.subjectSars-cov-2
dc.subjectFav00a
dc.subjectAmizon
dc.titleEnisamium Inhibits SARS-CoV-2 RNA Synthesis.
dc.typeArticle
dc.date.updated2021-10-30T01:13:02Z
prism.issueIdentifier9
prism.publicationNameBiomedicines
prism.volume9
dc.identifier.doi10.17863/CAM.77535
dcterms.dateAccepted2021-09-14
rioxxterms.versionofrecord10.3390/biomedicines9091254
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidElli, Stefano [0000-0003-0686-2480]
dc.contributor.orcidMüller, Lutz [0000-0002-3633-1309]
dc.contributor.orcidTe Velthuis, Aartjan JW [0000-0002-5129-3953]
dc.identifier.eissn2227-9059
pubs.funder-project-idZonMw (10430 01 201 0018)
pubs.funder-project-idWellcome Trust (206579/Z/17/Z)
cam.issuedOnline2021-09-17


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International